Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- With New CV Drugs, Gilead Tests Its Commitment to Efficiency
- Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan. Combined with Gilead's purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a...
- Blog posts 2009-04-03
Additional Resources
- Myogen Reports Positive Results for Darusentan Phase 2b Trial in Resistant Hypertension and Teva Announces Tentative Approval of Granisetron Hydrochloride Injection.
- M2 PRESSWIRE-18 August 2005-US Financial Network: Myogen Reports Positive Results for Darusentan Phase 2b Trial in Resistant Hypertension and Teva Announces Tentative Approval of Granisetron Hydrochloride InjectionC1994-2005 M2 COMMUNICATIONS LTD RDATE:18082008 City of Industry, CA - Biotechnology industry news provided by...
- Research articles 2005-08-18
- Gilead Sciences Q4 2006 Earnings Call Transcript
- Question-and-Answer SessionOperator [Operator Instructions]. And your first question comes from the line of Meg Malloy with Goldman Sachs. Please proceed. Meg Malloy - Goldman Sachs Thanks very much for the call and for taking the questions. Just two very quick ones on the pipeline. First,...
- Earnings calls 2007-01-31
- Stock Movers of Note 8/18.
- M2 PRESSWIRE-18 August 2005-StreetInsider.com: Stock Movers of Note 8/18C1994-2005 M2 COMMUNICATIONS LTD RDATE:18082005 Streetinsider.com's Stock Movers of Note: Myogen (Nasdaq: MYOG), Catuity (Nasdaq: CTTY), Genelabs Technologies (Nasdaq: GNLB), Harman Intl (NYSE: HAR), Six Flags (NYSE: PKS), Tommy Hilfiger (NYSE: TOM)...
- Research articles 2005-08-18
- Gilead Sciences: Stock in Decline or Great Buying Opportunity?
- VFC submits: After trading at forty eight dollars just three weeks ago on news of the Swine Flu pandemic , shares of Gilead Sciences GILD have embarked on a downward trend that now has the stock trading below forty three dollars, closing Thursday at $42.56. Gilead Sciences is a...
- External links 2009-05-22
- As Gilead Plows Ahead on Heart Drugs, Market Frowns on Its Stock
- As summer starts, the bloom seems to be off the rose for Gilead. Its positive Phase III results for heart drug darusentan boosted the stock in April to $48.37, but since then it's fallen back to around $43. by Jim Edwards
- Blog posts 2009-06-02
- << Previous
- page 1 of 1
- Next >>
